| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.
|
N Engl J Med
|
2012
|
10.07
|
|
2
|
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.
|
N Engl J Med
|
2012
|
9.69
|
|
3
|
New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment.
|
Blood
|
2008
|
7.73
|
|
4
|
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.
|
Blood
|
2016
|
4.94
|
|
5
|
European consensus on grading bone marrow fibrosis and assessment of cellularity.
|
Haematologica
|
2005
|
4.34
|
|
6
|
DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status.
|
J Clin Oncol
|
2010
|
4.18
|
|
7
|
A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment).
|
Blood
|
2009
|
3.76
|
|
8
|
Mutations and prognosis in primary myelofibrosis.
|
Leukemia
|
2013
|
3.13
|
|
9
|
Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment.
|
Leukemia
|
2007
|
2.61
|
|
10
|
Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis.
|
Blood
|
2013
|
2.60
|
|
11
|
Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis.
|
Blood
|
2014
|
1.62
|
|
12
|
Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients.
|
Leukemia
|
2010
|
1.44
|
|
13
|
Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis?
|
Blood
|
2013
|
1.42
|
|
14
|
A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis.
|
Haematologica
|
2015
|
1.10
|
|
15
|
Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study.
|
Blood
|
2014
|
1.06
|
|
16
|
Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group.
|
Am J Hematol
|
2016
|
0.94
|
|
17
|
Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group.
|
Leukemia
|
2015
|
0.93
|
|
18
|
Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis.
|
Leukemia
|
2016
|
0.87
|
|
19
|
A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis.
|
Leukemia
|
2017
|
0.77
|
|
20
|
Update from the latest WHO classification of MPNs: a user's manual.
|
Hematology Am Soc Hematol Educ Program
|
2016
|
0.75
|
|
21
|
Driver mutations' effect in secondary myelofibrosis: An international multicenter study based on 781 patients.
|
Leukemia
|
2016
|
0.75
|
|
22
|
Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation.
|
Blood
|
2017
|
0.75
|
|
23
|
MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis.
|
J Clin Oncol
|
2017
|
0.75
|